PMID- 33389914
OWN - NLM
STAT- MEDLINE
DCOM- 20211028
LR  - 20220531
IS  - 1940-4379 (Electronic)
IS  - 1050-6934 (Linking)
VI  - 30
IP  - 1
DP  - 2020
TI  - Safety and Efficacy of Cultured/Noncultured Mesenchymal Stromal Cells without 
      Concurrent Surgery for Knee Osteoarthritis: A Systematic Review of Randomized 
      Controlled Trials.
PG  - 31-47
LID - 10.1615/JLongTermEffMedImplants.2020035281 [doi]
AB  - The quantity of studies investigating mesenchymal stromal cells (MSCs) for knee 
      osteoarthritis (OA) treatment is not restricted, unlike the amount of randomized 
      controlled trials (RCTs) that can be found in the literature. MSCs demonstrate a 
      promising potential for safe pain relief of OA, yet indeterminate conclusions 
      prevail due to heterogeneous reporting and study design. By evaluating PubMed and 
      ScienceDirect for RCTs that describe patient-reported outcome measures (PROMs) 
      and adverse events (AEs), we investigate safety and efficacy of MSCs for knee OA 
      unaccompanied by adjuvant surgical intervention. This systematic review is 
      performed in alignment with preferred reported items for systematic reviews and 
      meta-analyses guidelines. In addition to PROMs and AEs, we review included 
      studies for stromal cell variants, follow-up, and imaging modalities, reporting 
      our results in tables and text. Twelve studies that ranged from 1 wk to 4 yr and 
      examined 428 patients and 856 knees met inclusion criteria. Six studies (50%) 
      evaluated bone marrow MSCs, five (42%) evaluated adipose-derived MSCs, and one 
      (8%) evaluated umbilical cord MSCs. All studies reported significant PROM 
      improvement. Mean improvements in the visual analog scale and Western Ontario and 
      McMaster Universities Arthritis Index, ranging from 0 to 40 and 10 to 32 points, 
      respectively, were observed. Of 343 total patients, 135 (39%) experienced AEs. 
      Whereas most AEs involved self-limiting knee swelling and pain, only three (0.8%) 
      were severe enough to require overnight hospitalization. MSCs without adjuvant 
      surgery offer a safe and efficacious conservative treatment option in knee OA 
      patients by alleviating and decreasing pain for up to 12 mo. However, study 
      limitations and contradictory findings require more evidence regarding cartilage 
      repair.
FAU - Hall, Michael
AU  - Hall M
AD  - University of California, Riverside School of Medicine, 92521 UCR Botanic Gardens 
      Rd, Riverside, CA 92507.
FAU - McCafferty, Joseph
AU  - McCafferty J
AD  - New York Medical College, School of Medicine, Valhalla, NY 10595.
FAU - Agarwalla, Avinesh
AU  - Agarwalla A
AD  - Department of Orthopaedic Surgery, Westchester Medical Center, Valhalla, NY 
      10595.
FAU - Nwachuku, Ikenna
AU  - Nwachuku I
AD  - University of Southern California, Department of Orthopedic Surgery, 2051 Marengo 
      St., Boyle Heights, Los Angeles County, CA.
FAU - Liu, Joseph N
AU  - Liu JN
AD  - Department of Orthopaedic Surgery, Loma Linda University Medical Center, Loma 
      Linda, CA 92354.
FAU - Amin, Nirav H
AU  - Amin NH
AD  - Restore Orthopedics, Orange, CA 92868.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
PL  - United States
TA  - J Long Term Eff Med Implants
JT  - Journal of long-term effects of medical implants
JID - 9110830
MH  - Humans
MH  - Injections, Intra-Articular
MH  - *Mesenchymal Stem Cell Transplantation
MH  - *Mesenchymal Stem Cells
MH  - *Osteoarthritis, Knee/surgery
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
EDAT- 2021/01/04 06:00
MHDA- 2021/10/29 06:00
CRDT- 2021/01/03 20:44
PHST- 2021/01/03 20:44 [entrez]
PHST- 2021/01/04 06:00 [pubmed]
PHST- 2021/10/29 06:00 [medline]
AID - 32d222c9780a9dce,430201f7322a4ad5 [pii]
AID - 10.1615/JLongTermEffMedImplants.2020035281 [doi]
PST - ppublish
SO  - J Long Term Eff Med Implants. 2020;30(1):31-47. doi: 
      10.1615/JLongTermEffMedImplants.2020035281.